about
Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissuesEffects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularizationHuman kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancerExpression of androgen receptor and prostate-specific antigen in male breast carcinomaProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesReconnoitring the status of prostate specific antigen and its role in womenDifferentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progressionDown-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissuesThe emerging roles of human tissue kallikreins in cancerThe treatment of advanced renal cell cancer with high-dose oral thalidomideKallikrein gene downregulation in breast cancer.Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity.Expression, purification, and characterization of active recombinant prostate-specific antigen in Pichia pastoris (yeast).Novel peptide inhibitors of human kallikrein 2.The role of angiogenesis in prostate and other urologic cancers: a review.The discovery of compounds that stimulate the activity of kallikrein-related peptidase 3 (KLK3).Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activityThe role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer.Prostate-specific antigen modulates the expression of genes involved in prostate tumor growthSerum total PSA and free PSA in breast tumors.Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate CancerAngiogenesis in non-small cell lung cancer. A new target for therapy.Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.Protease-activated drug development.Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase 3 (KLK3).Isolation and characterization of circulating tumor cells in prostate cancer.Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.Development of peptides specifically modulating the activity of KLK2 and KLK3.New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.Antiangiogenic properties of prostate-specific antigen (PSA).Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.Targeting kallikrein-related peptidases in prostate cancer.Biomarker development, from bench to bedside.Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system.Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
P2860
Q22253907-D8E27E02-AAC8-4A2B-9A06-4AF24E15B6DFQ24630406-A7C466E5-B430-4914-9533-0E88D91C3B4DQ24642830-F85F2DAE-6DF8-49A5-8AAD-AE2A45A41CEEQ24803812-AA19F8D1-3408-4025-A419-40DE7437E96CQ26865810-7CB2D478-106D-4095-816D-CA1DF6B9FBDBQ26995569-C1E1795E-4E1E-44AE-8B43-130368CB6BFDQ28144159-6590309B-A07B-4718-8354-CF60866E63E3Q28214483-E9A2F29F-F2BC-4C95-9509-C6CAA1D8D0E1Q28290701-3C06DD48-83F8-4B10-9ECC-17945CCC7867Q28361231-810E3ABF-03D2-4F8D-B23E-396AED2A868DQ30438640-E9CDD970-E12A-46FE-981D-6A9AC802B3B3Q30933370-09EA9832-01F4-4B14-B753-C19D3B6DF627Q32162109-427D6DB7-7AE5-4C90-B5AF-1F5BE216A2A2Q33235991-A0DCF7A9-07DD-4BBC-96A8-490B111726FDQ33955367-347020FB-71D4-42CA-A6C2-C0AC0C579DA8Q34033411-D074FBB2-338D-467F-9D84-F2CBDF2E6BB8Q34215885-22E19764-3EF5-4798-9C91-CC1422036F70Q34447102-B8215DC9-4AF6-456E-AF1C-85AD6A5DC822Q34534087-E85B70CC-E381-4944-9AB1-BDF264C4F4D9Q34768349-EC70D71E-7C10-4FBB-A4E9-8EA66EFAC862Q35022387-45A699F4-C5BF-4E40-BA10-7AA80EAB8C5EQ35048230-B9083DC3-5B65-4557-8F18-B982A2B089C6Q35327105-D09F682E-D5C7-4047-BB92-715DDF079DE5Q35627784-4914F763-0EAF-4C75-8ABF-8D8AFD5B2FFAQ35748176-5D5CDA47-E307-429A-9659-79B9A6CAFD37Q35811508-364262A4-A049-4714-9A1A-0BA5435F33B1Q35838103-B534E77B-177A-40F0-93FE-33605EBF320FQ35861497-FD33D805-9E9E-4E2B-A0C1-FFA74E4C6EA8Q36087908-01CD80D9-8017-4362-B0AC-44BA542A3F36Q36310363-3A6FFE39-212B-48B3-A84C-B745F76F78D8Q36519378-23F841D5-73F5-499F-90A2-60901D7FAB3AQ36519383-9771EB32-E36F-4DF6-8E70-DD43A79C62E9Q37216674-AA7086A1-79D9-46F9-B278-B15E8F567BD6Q37453804-404EE863-03F4-4594-B135-CDD61778AF3DQ37529537-FDAAF44C-C282-4206-9ECC-B71F11838D88Q37697815-89DF4C41-8A4C-42A7-8A52-B6D359AF8387Q38191293-CA937C5D-5378-4620-BE25-918824785A7DQ38569348-19580C8A-22E1-4758-88E1-A19E3CB2DAB0Q38571586-F65A9501-51EA-4648-9602-E35283532339Q38737293-1007C677-6181-4615-B17F-024DF7D5202A
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Antiangiogenic activity of prostate-specific antigen.
@en
type
label
Antiangiogenic activity of prostate-specific antigen.
@en
prefLabel
Antiangiogenic activity of prostate-specific antigen.
@en
P2093
P356
P1476
Antiangiogenic activity of prostate-specific antigen.
@en
P2093
P304
P356
10.1093/JNCI/91.19.1635
P407
P577
1999-10-01T00:00:00Z